<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537549</url>
  </required_header>
  <id_info>
    <org_study_id>IRB1006011088</org_study_id>
    <nct_id>NCT01537549</nct_id>
  </id_info>
  <brief_title>Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy</brief_title>
  <official_title>An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that alpha-lipoic acid and L-acetyl carnitine may have some
      neuroprotective activities and it is hoped that they could be helpful for people with
      neurodegenerative illnesses such as progressive supranuclear palsy (PSP).

      The purpose of this study is to find out whether the nutritional supplement alpha-lipoic
      acid/L-acetyl carnitine is safe and well-tolerated in individuals with PSP when given daily,
      and whether it affects their well-being, brain scan measurements and blood tests that measure
      the energy metabolism in cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple lines of evidence support mitochondrial dysfunction and oxidative stress playing a
      role in the pathogenesis of atypical Parkinsonism, including PSP. Such dysfunction may well
      contribute to the tau pathology that is well-recognized in PSP, thus providing a link between
      the two processes. This pathway therefore represents an excellent potential target for novel
      therapeutic intervention in neurodegenerative disorders, and a number of well-tolerated and
      safe nutritional supplements have been identified that appear to augment mitochondrial
      function, and improve oxidative stress.

      Alpha-lipoic acid and L-acetyl carnitine are two nutritional supplements that have received
      increasing attention as potential neuroprotective interventions in neurodegenerative and
      other disease states. Alpha-lipoic acid/L-acetyl carnitine had been demonstrated to improve
      learning in aged beagles over 2 months of administration, and showed a trend to improve
      cognitive function in a mouse model of Alzheimer's disease (human apoE4 transgene). Moreover,
      alpha-lipoic acid/L-acetyl carnitine was neuroprotective in a mouse model of Parkinson's
      disease (rotenone-induced parkinsonism), with effects including decreased oxidative stress,
      and increased mitochondrial biogenesis. In fibroblasts derived from individuals with
      Alzheimer's disease, alpha-lipoic acid/L-acetyl carnitine reduced increased levels of
      oxidative stress. In healthy men exposed to intensive exercise, alpha-lipoic acid provided
      antioxidant effects systemically (decreased peroxidation). L-acetyl carnitine improved
      neuroimaging correlates of cerebral blood flow in 30 subjects with dementia. These
      nutritional supplements have been safe and well-tolerated, and they have been tested in age
      groups including children, up to the elderly. Alpha-lipoic acid had been successfully
      administered over an extended period in an open-label trial in Alzheimer's disease.
      Importantly, it appeared that the effects of alpha-lipoic acid and L-acetyl carnitine when
      administered together were significantly augmented (100-1000 times), as opposed to when
      administered separately. This therefore provided a strong rationale to test the two in
      combination.

      In addition to monitoring clinical features, we had also chosen to test physiologic effects
      of alpha-lipoic acid/L-acetyl carnitine in our PSP subjects using two biomarkers that provide
      measures of mitochondrial function and oxidative stress. This was particularly important,
      since both supplements may act by multiple mechanisms. 1H MRSI is a technique that provides
      insight into the metabolism of several endogenous brain compounds, most notably
      N-acetyl-L-aspartate (NAA), choline-containing compounds (Cho), and creatine and
      phosphocreatine (Cr). A number of studies of mitochondrial function had firmly established
      the utility of 1H MRSI in probing potential mitochondrial energy metabolism dysfunction. 31P
      MRSI provided complementary information to probe in vivo mitochondrial energy metabolism and
      tissue energetics. In addition, we proposed using markers of oxidative damage (including
      8-hydroxydeoxyguanosine) as well as metabolomic analysis to test a composite panel of
      quantitative measures in plasma. We used an established metabolomic platform that has proven
      to identify specific combinations of metabolites differing between neurodegenerative disease
      states (including Parkinson's disease, Huntington's disease) and healthy controls. Our
      overall aim was to generate an &quot;oxidative biomarker&quot; and &quot;metabolomic read-out&quot; of the
      peripheral biochemical effects of alpha-lipoic acid/L-acetyl carnitine in PSP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2010</start_date>
  <completion_date type="Actual">April 7, 2015</completion_date>
  <primary_completion_date type="Actual">September 24, 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>at 25 weeks</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral Oxidative Stress Markers</measure>
    <time_frame>at baseline and at week 5</time_frame>
    <description>changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>Juvenon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-lipoic acid and L-acetyl carnitine</intervention_name>
    <description>alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months</description>
    <arm_group_label>Juvenon</arm_group_label>
    <other_name>Juvenon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable PSP by NINDS/PSP workshop criteria (see patient folder)

          -  Age 40-75 years

          -  Able to undergo MRI

          -  Absence of significant medical, psychiatric, and other neurological disease

          -  Stable intake of supplements and medication

        Exclusion Criteria:

          -  Failure to meet probable PSP diagnosis by NINDS/PSP workshop criteria

          -  unable to comply with informed consent process

          -  unable to undergo MRI

          -  presence of significant medical, psychiatric (incl MDD) or other neurological (incl
             epilepsy, brain tumor, stroke) disease

          -  possibility of pregnancy (negative test required in women of childbearing age)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Henchcliffe, MD DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>February 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 12, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Progressive supranuclear palsy</keyword>
  <keyword>alpha-lipoic acid</keyword>
  <keyword>L-acetyl carnitine</keyword>
  <keyword>antioxidant</keyword>
  <keyword>magnetic resonance spectroscopy</keyword>
  <keyword>neurodegeneration</keyword>
  <keyword>glutathione</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Acetylcarnitine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Juvenon</title>
          <description>alpha-lipoic acid and L-acetyl carnitine: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Juvenon</title>
          <description>alpha-lipoic acid and L-acetyl carnitine: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Incidence and severity of adverse events</description>
        <time_frame>at 25 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Juvenon</title>
            <description>alpha-lipoic acid and L-acetyl carnitine: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Incidence and severity of adverse events</description>
          <population>ITT</population>
          <units>Number of Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Oxidative Stress Markers</title>
        <description>changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy</description>
        <time_frame>at baseline and at week 5</time_frame>
        <population>per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Juvenon at Baseline</title>
            <description>at Baseline, no drug taken yet</description>
          </group>
          <group group_id="O2">
            <title>Juvenon at 1 Month</title>
            <description>alpha-lipoic acid and L-acetyl carnitine: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily (1 month)</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Oxidative Stress Markers</title>
          <description>changes of cerebral lactate and glutathione levels as determined by magnetic resonance spectroscopy</description>
          <population>per Protocol</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.67"/>
                    <measurement group_id="O2" value="4.6" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At Baseline, Week 5, and Week 25</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Juvenon</title>
          <description>alpha-lipoic acid and L-acetyl carnitine: alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Leg Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastro Disturbances</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Odor of Urine, Breath, or Sweat</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Other Possible Effects</sub_title>
                <description>Restlessness, insomnia, dizziness, seizures</description>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchoconstriction, Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rashes, Itching, Swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Claire Henchcliffe</name_or_title>
      <organization>Weill Cornell Medicine</organization>
      <phone>2127462584</phone>
      <email>clh2007@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

